Cargando…
Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons
Diabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD(+) levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD(+)) levels to prevent dementia. We tested if the administration of the precursor of NAD(+), ni...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313029/ https://www.ncbi.nlm.nih.gov/pubmed/32466541 http://dx.doi.org/10.3390/ijms21113756 |
_version_ | 1783549864435515392 |
---|---|
author | Chandrasekaran, Krish Choi, Joungil Arvas, Muhammed Ikbal Salimian, Mohammad Singh, Sujal Xu, Su Gullapalli, Rao P Kristian, Tibor Russell, James William |
author_facet | Chandrasekaran, Krish Choi, Joungil Arvas, Muhammed Ikbal Salimian, Mohammad Singh, Sujal Xu, Su Gullapalli, Rao P Kristian, Tibor Russell, James William |
author_sort | Chandrasekaran, Krish |
collection | PubMed |
description | Diabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD(+) levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD(+)) levels to prevent dementia. We tested if the administration of the precursor of NAD(+), nicotinamide mononucleotide (NMN), can prevent diabetes-induced memory deficits. Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ). After 3 months of diabetes, hippocampal NAD(+) levels were decreased (p = 0.011). In vivo localized high-resolution proton magnetic resonance spectroscopy (MRS) of the hippocampus showed an increase in the levels of glucose (p < 0.001), glutamate (p < 0.001), gamma aminobutyric acid (p = 0.018), myo-inositol (p = 0.018), and taurine (p < 0.001) and decreased levels of N-acetyl aspartate (p = 0.002) and glutathione (p < 0.001). There was a significant decrease in hippocampal CA1 neuronal volume (p < 0.001) and neuronal number (p < 0.001) in the Diabetic rats. Diabetic rats showed hippocampal related memory deficits. Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months. NMN increased brain NAD(+) levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione. NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control. In hippocampal protein extracts from Diabetic rats, SIRT1 and PGC-1α protein levels were decreased, and acetylation of proteins increased. NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins. Our results indicate that NMN increased brain NAD(+), activated the SIRT1 pathway, preserved mitochondrial oxidative phosphorylation (OXPHOS) function, prevented neuronal loss, and preserved cognition in Diabetic rats. |
format | Online Article Text |
id | pubmed-7313029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73130292020-06-29 Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons Chandrasekaran, Krish Choi, Joungil Arvas, Muhammed Ikbal Salimian, Mohammad Singh, Sujal Xu, Su Gullapalli, Rao P Kristian, Tibor Russell, James William Int J Mol Sci Article Diabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD(+) levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD(+)) levels to prevent dementia. We tested if the administration of the precursor of NAD(+), nicotinamide mononucleotide (NMN), can prevent diabetes-induced memory deficits. Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ). After 3 months of diabetes, hippocampal NAD(+) levels were decreased (p = 0.011). In vivo localized high-resolution proton magnetic resonance spectroscopy (MRS) of the hippocampus showed an increase in the levels of glucose (p < 0.001), glutamate (p < 0.001), gamma aminobutyric acid (p = 0.018), myo-inositol (p = 0.018), and taurine (p < 0.001) and decreased levels of N-acetyl aspartate (p = 0.002) and glutathione (p < 0.001). There was a significant decrease in hippocampal CA1 neuronal volume (p < 0.001) and neuronal number (p < 0.001) in the Diabetic rats. Diabetic rats showed hippocampal related memory deficits. Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months. NMN increased brain NAD(+) levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione. NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control. In hippocampal protein extracts from Diabetic rats, SIRT1 and PGC-1α protein levels were decreased, and acetylation of proteins increased. NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins. Our results indicate that NMN increased brain NAD(+), activated the SIRT1 pathway, preserved mitochondrial oxidative phosphorylation (OXPHOS) function, prevented neuronal loss, and preserved cognition in Diabetic rats. MDPI 2020-05-26 /pmc/articles/PMC7313029/ /pubmed/32466541 http://dx.doi.org/10.3390/ijms21113756 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chandrasekaran, Krish Choi, Joungil Arvas, Muhammed Ikbal Salimian, Mohammad Singh, Sujal Xu, Su Gullapalli, Rao P Kristian, Tibor Russell, James William Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons |
title | Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons |
title_full | Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons |
title_fullStr | Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons |
title_full_unstemmed | Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons |
title_short | Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons |
title_sort | nicotinamide mononucleotide administration prevents experimental diabetes-induced cognitive impairment and loss of hippocampal neurons |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313029/ https://www.ncbi.nlm.nih.gov/pubmed/32466541 http://dx.doi.org/10.3390/ijms21113756 |
work_keys_str_mv | AT chandrasekarankrish nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons AT choijoungil nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons AT arvasmuhammedikbal nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons AT salimianmohammad nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons AT singhsujal nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons AT xusu nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons AT gullapalliraop nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons AT kristiantibor nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons AT russelljameswilliam nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons |